LAUSANNE, SWITZERLAND

Bata Group Celebrates Founder’s Day: A Global Day to Remember and to Give Back

Bata Group, the renowned footwear brand with a rich heritage, is excited to announce the upcoming celebration of its annual Founder’s Day on September 21, 2023. This global event commemorates the remarkable journey of Bata and brings together employees, customers, and communities worldwide to embrace the spirit of unity. Founder’s Day holds immense significance for […]

thaipr.net

31 ส.ค. 66

Airbus Extends Partnership with Astrocast to Further Enhance Satellite IoT Technology

Airbus partnership extension reaffirms commitment to support Astrocast’s SatIoT technology roadmap, reinforcing Astrocast’s position as the leading provider of cost-effective and reliable satellite IoT solutions. Astrocast, a leading satellite IoT operator, announces the extension of its partnership with Airbus Defence and Space (Airbus), a global leader in the aerospace industry. This partnership enhances the capabilities […]

thaipr.net

24 ก.ค. 66

DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM

Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the first patient dosed of their first-in-human, phase 1/2 study, GaLuCi™. The first patient was screened and dosed at the Australian-based Peter MacCallum Cancer Centre. This multicenter international trial, evaluating a radioligand theranostic pair will…

thaipr.net

23 มี.ค. 66

DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY

Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA…

thaipr.net

2 มี.ค. 66

DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS

–  Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. –  Debiopharm is developing Debio 4126, a novel 3-month extended-release octreotide formulation, to optimize acromegaly and GEP-NET patient care by reducing injection frequency, which translates into…

thaipr.net

12 ม.ค. 66

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research   Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Akihide Yoshimi and for Translational…

thaipr.net

3 ต.ค. 65

Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence

Debiopharm Innovation Fund strategically invests in Whitelab Genomics’ mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm (www.Debiopharm.com), announced today their investment in Whitelab Genomics alongside French Venture Capital company, Omnes Capital, in […]

thaipr.net

14 ก.ย. 65

ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS

International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly address the threat of AMR Debiopharm will join the action-focused discussions around […]

thaipr.net

8 ก.ย. 65

Philips Projection introduces the Philips Screeneo U4

The company’s all-new Ultra-Short-Throw projector. Philips Projection is delighted to announce the launch of the Philips Screeneo U4, an ultra-short-throw projector that provides an 80″ True Full HD picture while positioned as close as 12″ (30.5cm) away. Exclusively available for pre-order on the online innovation platform, Indiegogo, the Screeneo U4 has already received great interest from thousands […]

thaipr.net

15 มิ.ย. 65

DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES

Pre-clinical & clinical exploratory poster presentations to highlight oncology results withDebio 0123, xevinapant, and Multilink™ technology for antibody drug conjugates Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical…

thaipr.net

12 เม.ย. 65
1 2

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.